. Author manuscript; available in PMC: 2012 Feb 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):181–189. doi: 10.1097/QAI.0b013e3182174a76

TABLE 1.

KIR and HLA-B and HLA-C Genotypes and Clinical Parameters of Patients Stratified According to the Presence or Absence of Natural Killer Cell Responses to HIV-1 Peptides

graphic file with name nihms306709f3.jpg

nd: not determined; Env: envelope peptide pool, Reg: regulatory regions (Tat, Rev, Vif, Vpu, and Vpr) peptides combined

C1C1: two group-1 HLA-C alleles, C2C2: two group-2 HLA-C alleles, C1C2: heterozygote; Bw4/4: two HLA-Bw6 alleles, Bw6/6: two HLA-Bw6 alleles, Bw4/6: heterozygote 2DL, 3DL: inhibitory KIR; 2DS, 3DS: activating KIR; 2DP1, 3DP1: pseudogenes